Limits...
Development of Paramyosin as a Vaccine Candidate for Schistosomiasis.

Jiz MA, Wu H, Olveda R, Jarilla B, Kurtis JD - Front Immunol (2015)

Bottom Line: Schistosomiasis, caused by three principal species of diecious trematodes (flatworms), currently afflicts over 250 million individuals, results in an estimated 2-15% chronic disability, and contributes to poor health and economic stagnation in endemic areas.Paramyosin (Pmy), an invertebrate muscle-associated protein, has emerged as a promising vaccine candidate for both Schistosoma mansoni and Schistosoma japonicum.Herein, we discuss the discovery of Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies of naturally occurring immune responses to Pmy in prospective, observational human studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Health, Research Institute for Tropical Medicine , Manila , Philippines.

ABSTRACT
Schistosomiasis, caused by three principal species of diecious trematodes (flatworms), currently afflicts over 250 million individuals, results in an estimated 2-15% chronic disability, and contributes to poor health and economic stagnation in endemic areas. Although schistosomiasis is effectively treated with praziquantel, rapid reinfection with rebound morbidity precludes effective control based on chemotherapy alone and justifies current efforts to develop vaccines for these parasites. Paramyosin (Pmy), an invertebrate muscle-associated protein, has emerged as a promising vaccine candidate for both Schistosoma mansoni and Schistosoma japonicum. Herein, we discuss the discovery of Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies of naturally occurring immune responses to Pmy in prospective, observational human studies. We conclude with a proposed developmental plan to move Pmy toward Phase I clinical trials.

No MeSH data available.


Related in: MedlinePlus

Chromatographic purification of S. japonicum paramyosin. A pET-30 plasmid containing paramyosin was expressed and purified similarly as described (28). Lane 1, inclusion body preparation; lane 2, anion exchange chromatography; lane 3, size exclusion chromatography; lane 4, purified S. japonicum paramyosin with a thioredoxin fusion tag. Reprinted from Ref. (30).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4508564&req=5

Figure 2: Chromatographic purification of S. japonicum paramyosin. A pET-30 plasmid containing paramyosin was expressed and purified similarly as described (28). Lane 1, inclusion body preparation; lane 2, anion exchange chromatography; lane 3, size exclusion chromatography; lane 4, purified S. japonicum paramyosin with a thioredoxin fusion tag. Reprinted from Ref. (30).

Mentions: We have conducted extensive functional, biochemical, biophysical, and immunologic analyses on rSj97 to demonstrate that our recombinant protein is free of concerning contaminants, is correctly folded, and has appropriate functional properties. Electrophoretic mobility and purity (Figure 2), sterility, endotoxin level (by FDA approved test), residual SDS concentration, identity (LC-MS), secondary and tertiary structural analysis (CD), collagen binding, IgG binding, and stability (>12 months) gave expected results (31).


Development of Paramyosin as a Vaccine Candidate for Schistosomiasis.

Jiz MA, Wu H, Olveda R, Jarilla B, Kurtis JD - Front Immunol (2015)

Chromatographic purification of S. japonicum paramyosin. A pET-30 plasmid containing paramyosin was expressed and purified similarly as described (28). Lane 1, inclusion body preparation; lane 2, anion exchange chromatography; lane 3, size exclusion chromatography; lane 4, purified S. japonicum paramyosin with a thioredoxin fusion tag. Reprinted from Ref. (30).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4508564&req=5

Figure 2: Chromatographic purification of S. japonicum paramyosin. A pET-30 plasmid containing paramyosin was expressed and purified similarly as described (28). Lane 1, inclusion body preparation; lane 2, anion exchange chromatography; lane 3, size exclusion chromatography; lane 4, purified S. japonicum paramyosin with a thioredoxin fusion tag. Reprinted from Ref. (30).
Mentions: We have conducted extensive functional, biochemical, biophysical, and immunologic analyses on rSj97 to demonstrate that our recombinant protein is free of concerning contaminants, is correctly folded, and has appropriate functional properties. Electrophoretic mobility and purity (Figure 2), sterility, endotoxin level (by FDA approved test), residual SDS concentration, identity (LC-MS), secondary and tertiary structural analysis (CD), collagen binding, IgG binding, and stability (>12 months) gave expected results (31).

Bottom Line: Schistosomiasis, caused by three principal species of diecious trematodes (flatworms), currently afflicts over 250 million individuals, results in an estimated 2-15% chronic disability, and contributes to poor health and economic stagnation in endemic areas.Paramyosin (Pmy), an invertebrate muscle-associated protein, has emerged as a promising vaccine candidate for both Schistosoma mansoni and Schistosoma japonicum.Herein, we discuss the discovery of Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies of naturally occurring immune responses to Pmy in prospective, observational human studies.

View Article: PubMed Central - PubMed

Affiliation: Department of Health, Research Institute for Tropical Medicine , Manila , Philippines.

ABSTRACT
Schistosomiasis, caused by three principal species of diecious trematodes (flatworms), currently afflicts over 250 million individuals, results in an estimated 2-15% chronic disability, and contributes to poor health and economic stagnation in endemic areas. Although schistosomiasis is effectively treated with praziquantel, rapid reinfection with rebound morbidity precludes effective control based on chemotherapy alone and justifies current efforts to develop vaccines for these parasites. Paramyosin (Pmy), an invertebrate muscle-associated protein, has emerged as a promising vaccine candidate for both Schistosoma mansoni and Schistosoma japonicum. Herein, we discuss the discovery of Pmy, its development as a vaccine candidate in rodents and bovines, as well as studies of naturally occurring immune responses to Pmy in prospective, observational human studies. We conclude with a proposed developmental plan to move Pmy toward Phase I clinical trials.

No MeSH data available.


Related in: MedlinePlus